title: New onset atrial fibrillation after patent foramen ovale closure.
abstract: OBJECTIVE
  In this study, we evaluated the incidence of new onset atrial fibrillation (symptomatic or detected by routine ECG) after patent foramen ovale (PFO-) closure.
  
  
  BACKGROUND
  Although atrial fibrillation is known to occur in some patients following patent foramen ovale closure, the incidence and the risk associated with each device is not well known.
  
  
  METHODS
  We evaluated 1,349 consecutive patients who underwent PFO closure with an approved device and examined the incidence and risk factors associated with the development of atrial fibrillation. The patients had a mean age of 50 years and underwent PFO closure for cerebrovascular accident in 696 (51.6%), transient ischemic attack in 610 (45.2%), paradoxical embolism in 22 (1.6%), decompression sickness in 13 (0.9%), and other reasons including migraine headaches in 6 (0.4%) of cases.
  
  
  RESULTS
  Over a mean follow-up period of 38.1 +/- 28 months, 53 (3.9%) patients developed new onset atrial fibrillation, which is higher compared with an age-matched population. Of these, 33 (62.3%) patients developed atrial fibrillation within 4 weeks and 8 (15%) within 6 months following PFO closure (totally 77% from 0 to 6 months). The event consisted of a single paroxysm lasting less than 48 hr in 23 patients, resolving either spontaneously or with cardioversion. 40 (75.5%) patients were symptomatic at the time of diagnosis. Thirty (56.6%) patients developed chronic atrial fibrillation. On multivariate analysis, advanced age and use of the STARFlex device predicted atrial fibrillation.
  
  
  CONCLUSIONS
  The number of patients in whom atrial fibrillation was detected was relatively low. It is often a self-limited complication of PFO closure that may occur more frequently in elderly patients and those treated with the STARFlex device.
authors.affiliation: CardioVascular Center Frankfurt, Frankfurt, Germany.
authors.forename: Stephan
authors.initials: S
authors.lastname: Staubach
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Steinberg
authors.forename: Wibke
authors.initials: W
authors.lastname: Zimmermann
authors.forename: Nikolaus
authors.initials: N
authors.lastname: Wawra
authors.forename: Neil
authors.initials: N
authors.lastname: Wilson
authors.forename: Nina
authors.initials: N
authors.lastname: Wunderlich
authors.forename: Horst
authors.initials: H
authors.lastname: Sievert
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D006328:Cardiac Catheterization / Q000009:adverse effects* / Q000295:instrumentation; D002908:Chronic Disease; D004562:Electrocardiography; D005260:Female; D054092:Foramen Ovale, Patent / Q000628:therapy*; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D055989:Septal Occluder Device / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult